CVE-2017-18228
Remedy Mid Tier in BMC Remedy AR System 9.1 allows XSS via the ATTKey parameter in an arsys...
Remedy Mid Tier in BMC Remedy AR System 9.1 allows XSS via the ATTKey parameter in an arsys/servlet/AttachServlet request.
Attack profile
How easy it is to exploit
- Attack vector
- Network
- Complexity
- Low
- Privileges needed
- Low
- User interaction
- Required
What an attacker can affect
- Confidentiality
- Low
- Integrity
- Low
- Availability
- None
Exploit likelihood
What each source reports
NVD Score used
Remedy Mid Tier in BMC Remedy AR System 9.1 allows XSS via the ATTKey parameter in an arsys/servlet/AttachServlet request.
- Record
CVE-2017-18228- CVSS 3.0
- 5.4 Medium
CVSS:3.0/AV:N/AC:L/PR:L/UI:R/S:C/C:L/I:L/A:N - CVSS 2.0
- 3.5 Low
AV:N/AC:M/Au:S/C:N/I:P/A:N - Weakness
- CWE-79
- Updated
- 2026-11-02
CVE List No score
Remedy Mid Tier in BMC Remedy AR System 9.1 allows XSS via the ATTKey parameter in an arsys/servlet/AttachServlet request.
- Record
CVE-2017-18228- Updated
- 2026-11-02
EUVDEUVD-2017-9360 No score
Remedy Mid Tier in BMC Remedy AR System 9.1 allows XSS via the ATTKey parameter in an arsys/servlet/AttachServlet request.
- Record
EUVD-2017-9360- Updated
- 2026-11-03
GitHub AdvisoriesGHSA-xpwq-6mfc-rr7g
Remedy Mid Tier in BMC Remedy AR System 9.1 allows XSS via the ATTKey parameter in an arsys...
Remedy Mid Tier in BMC Remedy AR System 9.1 allows XSS via the ATTKey parameter in an arsys/servlet/AttachServlet request.
- Record
GHSA-xpwq-6mfc-rr7g- CVSS 3.0
- 5.4 Medium
CVSS:3.0/AV:N/AC:L/PR:L/UI:R/S:C/C:L/I:L/A:N - Weakness
- CWE-79
- Updated
- 2026-11-02
Affected products
History
| Recorded | Changed | Sources |
|---|---|---|
| aliases | EUVD | |
| first indexed | CVE List, GitHub Advisories, NVD |
Dates are when Every CVE recorded each change. Upstream dates may differ.
In short
CVE-2017-18228 is a medium vulnerability (CVSS 5.4) in Bmc Remedy Action Request System, published March 12, 2018. No source lists public exploit code. EPSS puts the chance of exploitation in the next 30 days at 0.51%, the 43rd percentile. No source names a fixed version.